-
12/21/2016
PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
-
10/19/2016
Positive Remimazolam phase III colonoscopy results presented at the 2016 american college of gastroenterology annual scientific meeting
-
09/22/2016
Remimazolam Phase III colonoscopy data to be presented at the American College of Gastroenterology 2016 Meeting
-
09/06/2016
PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
-
08/10/2016
PAION AG reports financial results for the first half-year of 2016
-
06/29/2016
PAION completes private placement in the amount of EUR 9.6 Million
-
06/24/2016
PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG
-
06/19/2016
PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy
-
04/11/2016
PAION successfully completes patient recruitment in Phase III study with Remimazolam for procedural sedation during colonoscopy
-
03/22/2016
PAION AG reports on business year and financial results 2015
-
02/18/2016
PAION reports about positive pre-NDA meeting with Japanese authority PMDA
-
02/12/2016
US-patent & trademark office grants substance patent for Remimazolam besylate
-
02/09/2016
PAION discontinues European Remimazolam Phase III Trial in cardiac surgery patients due to insufficient recruitment